Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma

被引：340

作者：

Grommes, Christian ^{[1
,2
,3
]}

Pastore, Alessandro ^{[4
]}

Palaskas, Nicolaos ^{[2
,18
]}

Tang, Sarah S. ^{[2
]}

Campos, Carl ^{[2
]}

Schartz, Derrek ^{[2
]}

Codega, Paolo ^{[2
]}

Nichol, Donna ^{[2
,19
]}

Clark, Owen ^{[2
]}

Hsieh, Wan-Ying ^{[2
]}

Rohle, Dan ^{[2
,20
]}

Rosenblum, Marc ^{[5
]}

Viale, Agnes ^{[6
]}

Tabar, Viviane S. ^{[7
]}

Brennan, Cameron W. ^{[7
]}

Gavrilovic, Igor T. ^{[1
,3
]}

Kaley, Thomas J. ^{[1
,3
]}

Nolan, Craig P. ^{[1
,3
]}

Omuro, Antonio ^{[1
,3
,21
]}

Pentsova, Elena ^{[1
,3
]}

Thomas, Alissa A. ^{[1
,22
]}

Tsyvkin, Elina ^{[8
,9
]}

Noy, Ariela ^{[8
,9
]}

Palomba, M. Lia ^{[8
,9
]}

Hamlin, Paul ^{[8
,9
]}

Sauter, Craig S. ^{[8
,9
]}

Moskowitz, Craig H. ^{[8
,9
]}

Wolfe, Julia ^{[1
]}

Dogan, Ahmet ^{[5
]}

Won, Minhee ^{[10
]}

Glass, Jon ^{[11
]}

Peak, Scott ^{[12
]}

Lallana, Enrico C. ^{[13
]}

Hatzoglou, Vaios ^{[14
]}

Reiner, Anne S. ^{[15
]}

Gutin, Philip H. ^{[7
]}

Huse, Jason T. ^{[2
,5
,23
,24
]}

Panageas, Katherine S. ^{[15
]}

Graeber, Thomas G. ^{[16
]}

Schultz, Nikolaus ^{[2
,6
,15
]}

DeAngelis, Lisa M. ^{[1
,3
]}

Mellinghoff, Ingo K. ^{[1
,2
,3
,17
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA

[3] Weill Cornell Med Coll, Dept Neurol, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, Dept Computat Biol Program, 1275 York Ave, New York, NY 10021 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA

[6] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, 1275 York Ave, New York, NY 10021 USA

[7] Mem Sloan Kettering Canc Ctr, Dept Neurosurg, 1275 York Ave, New York, NY 10021 USA

[8] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[9] Weill Cornell Med Coll, Dept Med, New York, NY USA

[10] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA

[11] Thomas Jefferson Univ, Dept Neurosurg, Philadelphia, PA 19107 USA

[12] Permanente Med Grp Inc, Dept Neurosurg, Sacramento, CA USA

[13] Permanente Med Grp Inc, Dept Neurooncol, Redwood City, CA USA

[14] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA

[15] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA

[16] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Crump Inst Mol Imaging, Los Angeles, CA USA

[17] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA

[18] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA

[19] Personal Genome Diagnost, Baltimore, MD USA

[20] Roche, Basel, Switzerland

[21] Univ Miami, Dept Neurol, Miami, FL USA

[22] Univ Vermont, Dept Neurol, Burlington, VT USA

[23] MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA

[24] MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA

来源：

CANCER DISCOVERY | 2017年 / 7卷 / 09期

关键词：

B-CELL LYMPHOMA; NF-KAPPA-B; GENE-EXPRESSION; TARGETING BTK; CANCER; MUTATIONS; PI3K; GENOME; HETEROGENEITY; HYBRIDIZATION;

D O I：

10.1158/2159-8290.CD-17-0613

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bruton tyrosine kinase (BTK) links the B-cell antigen receptor (BCR) and Toll-like receptors with NF-kappa B. The role of BTK in primary central nervous system (CNS) lymphoma (PCNSL) is unknown. We performed a phase I clinical trial with ibrutinib, the first-in-class BTK inhibitor, for patients with relapsed or refractory CNS lymphoma. Clinical responses to ibrutinib occurred in 10 of 13 (77%) patients with PCNSL, including five complete responses. The only PCNSL with complete ibrutinib resistance harbored a mutation within the coiled-coil domain of CARD11, a known ibrutinib resistance mechanism. Incomplete tumor responses were associated with mutations in the B-cell antigen receptor-associated protein CD79B. CD79B-mutant PCNSLs showed enrichment of mammalian target of rapamycin (mTOR)-related gene sets and increased staining with PI3K/mTOR activation markers. Inhibition of the PI3K isoforms p110a/p110d or mTOR synergized with ibrutinib to induce cell death in CD79B-mutant PCNSL cells. SIGNIFICANCE: Ibrutinib has substantial activity in patients with relapsed or refractory B-cell lymphoma of the CNS. Response rates in PCNSL were considerably higher than reported for diffuse large B-cell lymphoma outside the CNS, suggesting a divergent molecular pathogenesis. Combined inhibition of BTK and PI3K/mTOR may augment the ibrutinib response in CD79B-mutant human PCNSLs. (C) 2017 AACR.

引用

页码：1018 / 1029

页数：12

共 57 条

[1] Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma [J].

Abrey, LE ;

Batchelor, TT ;

Ferreri, AJM ;

Gospodarowicz, M ;

Pulczynski, EJ ;

Zucca, E ;

Smith, JR ;

Korfel, A ;

Soussain, C ;

DeAngelis, LM ;

Neuwelt, EA ;

O'Neill, BP ;

Thiel, E ;

Shenkier, T ;

Graus, F ;

van den Bent, M ;

Seymour, JF ;

Poortmans, P ;

Armitage, JO ;

Cavalli, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5034-5043

[2] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[3] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[4]

[Anonymous], 2015, AM SOC HEMATOLOGY

[5] Primary Central Nervous System Lymphomas: A Validation Study of Array-Based Comparative Genomic Hybridization in Formalin-Fixed Paraffin-Embedded Tumor Specimens [J].

Braggio, Esteban ;

McPhail, Ellen Remstein ;

Macon, William ;

Lopes, M. Beatriz ;

Schiff, David ;

Law, Mark ;

Fink, Stephanie ;

Sprau, Debra ;

Giannini, Caterina ;

Dogan, Ahmet ;

Fonseca, Rafael ;

O'Neill, Brian Patrick .

CLINICAL CANCER RESEARCH, 2011, 17 (13) :4245-4253

[6] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

[7] The Challenge of Primary Central Nervous System Lymphoma [J].

Carnevale, Julia ;

Rubenstein, James L. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (06) :1293-+

[8] Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology [J].

Cheng, Donavan T. ;

Mitchell, Talia N. ;

Zehir, Ahmet ;

Shah, Ronak H. ;

Benayed, Ryma ;

Syed, Aijazuddin ;

Chandramohan, Raghu ;

Liu, Zhen Yu ;

Won, Helen H. ;

Scott, Sasinya N. ;

Brannon, A. Rose ;

O'Reilly, Catherine ;

Sadowska, Justyna ;

Casanova, Jacklyn ;

Yannes, Angela ;

Hechtman, Jaclyn F. ;

Yao, Jinjuan ;

Song, Wei ;

Ross, Dara S. ;

Oultache, Alifya ;

Dogan, Snjezana ;

Borsu, Laetitia ;

Hameed, Meera ;

Nafa, Khedoudja ;

Arcila, Maria E. ;

Ladanyi, Marc ;

Berger, Michael F. .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (03) :251-264

[9] The quest to overcome resistance to EGFR-targeted therapies in cancer [J].

Chong, Curtis R. ;

Jaenne, Pasi A. .

NATURE MEDICINE, 2013, 19 (11) :1389-1400

[10] Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples [J].

Cibulskis, Kristian ;

Lawrence, Michael S. ;

Carter, Scott L. ;

Sivachenko, Andrey ;

Jaffe, David ;

Sougnez, Carrie ;

Gabriel, Stacey ;

Meyerson, Matthew ;

Lander, Eric S. ;

Getz, Gad .

NATURE BIOTECHNOLOGY, 2013, 31 (03) :213-219

← 1 2 3 4 5 6 →